International Journal of Clinical Oncology最新文献

{"title":"LH-RH agonist monotherapy for androgen receptor-positive recurrent and/or metastatic salivary gland cancer: a retrospective study.","authors":"Takuma Kishida, Tomohiro Enokida, Ryutaro Onaga, Nobukazu Tanaka, Yuta Hoshi, Takao Fujisawa, Ryo Kuboki, Hideki Tanaka, Susumu Okano, Makoto Tahara","doi":"10.1007/s10147-025-02785-3","DOIUrl":"10.1007/s10147-025-02785-3","url":null,"abstract":"<p><strong>Background: </strong>Although combination therapy consisting of a luteinizing hormone-releasing hormone (LH-RH) agonist and an Androgen receptor (AR) inhibitor has demonstrated promising clinical activity for recurrent and/or metastatic SGC (R/M SGC), few studies on LH-RH agonist monotherapy have been reported.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients with AR-positive, R/M SGC treated by monotherapy with LH-RH agonists in our institution from November 2004 to July 2023.</p><p><strong>Results: </strong>Nineteen patients were identified; the median age was 64 years (range 42-82), 10 had salivary duct carcinoma (52.6%), and 3 had adenocarcinoma, not otherwise specified (15.8%). LH-RH agonist monotherapy was delivered as first-line systemic therapy for R/M disease in 16 patients (84.2%). Nine patients (47.4%) achieved tumor size reduction in target lesions with a median tumor shrinkage of 11% (range 1-100%), resulting in an overall response rate and clinical benefit rate (rate of patients achieving a complete response, partial response, or stable disease lasting for at least 24 weeks) of 15.8% and 36.8%, respectively. The median duration of treatment with LH-RH agonist monotherapy was 5.1 months (range 0.3-63.4), accounting for 35.2% of the entire treatment period. Median progression-free survival and overall survival was 3.2 months (95% confidence interval (95% CI), 1.6-6.0) and 21.6 months (95% CI 9.9-34.4), respectively. No severe adverse events leading to treatment interruption or discontinuation were seen.</p><p><strong>Conclusion: </strong>LH-RH agonist monotherapy demonstrated a well-balanced profile between efficacy and safety and could be an alternative therapeutic option, especially for subjects not tolerable to combination therapy. (242 words).</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1562-1571"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous cryoablation versus robot-assisted partial nephrectomy for small renal cell carcinoma: a retrospective cost analysis at Japanese single-institution.","authors":"Mayu Uka, Toshihiro Iguchi, Kensuke Bekku, Tomoaki Yamanoi, Toshiharu Mitsuhashi, Hideo Gobara, Noriyuki Umakoshi, Takahiro Kawabata, Koji Tomita, Yusuke Matsui, Motoo Araki, Takao Hiraki","doi":"10.1007/s10147-025-02783-5","DOIUrl":"10.1007/s10147-025-02783-5","url":null,"abstract":"<p><strong>Background: </strong>No direct cost comparison has been conducted between percutaneous cryoablation (PCA) and robot-assisted partial nephrectomy (RAPN) for clinical T1a renal cell carcinoma (RCC) in Japan. This study aimed to compare their costs.</p><p><strong>Methods: </strong>We retrospectively analyzed data from 212 PCAs (including 155 with transcatheter arterial embolization) and 119 RAPN cases performed between December 2017 and May 2022.</p><p><strong>Results: </strong>PCA patients were older with higher American Society of Anesthesiologists scores, Charlson Comorbidity Index, and history of previous RCC treatment, cardiovascular disease, and antithrombotic drug use than RAPN patients. PCA was associated with a significantly shorter procedure time and hospitalization duration with fewer major complications than those associated with RAPN. While PCA incurred a slightly lower total cost (1,123,000 vs. 1,155,000 yen), it had a significantly higher procedural cost (739,000 vs. 693,000 yen) and markedly worse total (- 93,000 vs. 249,000 yen) and procedural income-expenditure balance (- 189,000 vs. 231,000 yen) than those of RAPN. After statistical adjustment, PCA demonstrated significantly higher total (difference: 114,000 yen) and procedural costs (difference: 72,000 yen), alongside significantly worse total (difference: - 358,000 yen) and procedural income-expenditure balances (difference: - 439,000 yen). The incremental cost-effectiveness ratio was more favorable for PCA than for RAPN.</p><p><strong>Conclusion: </strong>For high- risk patients, PCA demonstrated a safer option with shorter hospitalization duration than those of RAPN. Although PCA was more cost-effective, its higher procedural cost and unfavorable income-expenditure balance require careful evaluation, especially for large tumors that require three or more needles.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1621-1630"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative stereotactic body radiotherapy for spinal and non-spinal bone metastases: combining tradition and innovation.","authors":"Kei Ito, Naoki Nakamura","doi":"10.1007/s10147-025-02750-0","DOIUrl":"10.1007/s10147-025-02750-0","url":null,"abstract":"<p><p>Bone metastases can cause pain, fractures, radiculopathy, and metastatic epidural spinal cord compression, all of which substantially impair patients' quality of life. Conventional external beam radiotherapy (cEBRT) has been the standard treatment for symptomatic bone metastases. While the effectiveness and safety of cEBRT are well established, it has certain limitations, including a short duration of pain relief, limited long-term tumor control, and suboptimal efficacy against radioresistant tumors. Over the past decade, stereotactic body radiotherapy (SBRT) has been explored as a palliative treatment for bone metastases. SBRT enables the delivery of high doses of radiation to bone lesions by maximizing dose conformality. This treatment characteristic yields several clinical advantages, including considerable pain relief, durable tumor control, and efficacy against radioresistant tumors. SBRT has the potential to overcome the limitations of cEBRT and represents a promising approach that could revolutionize the treatment of bone metastases. This review addresses three clinical scenarios: painful spinal metastases, painful non-spinal bone metastases, and metastatic epidural spinal cord compression. For each scenario, we summarized the evidence for cEBRT and SBRT, highlighting the utility and potential of SBRT as an emerging treatment option.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1492-1499"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic factors and treatment patterns of the first recurrence of retroperitoneal liposarcoma.","authors":"Yoshiyuki Matsui, Shintaro Iwata, Konosuke Moritani, Aiko Maejima, Satoshi Nara, Yukinori Yamagata, Motokiyo Komiyama, Satoshi Kamio, Kan Yonemori, Akira Kawai, Hiroyuki Fujimoto","doi":"10.1007/s10147-025-02790-6","DOIUrl":"10.1007/s10147-025-02790-6","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify prognostic factors and treatment patterns at the first recurrence of retroperitoneal liposarcoma (LPS).</p><p><strong>Methods: </strong>Medical records of 150 patients who underwent resection for primary retroperitoneal LPS were reviewed. Of the 94 patients with local or distant recurrence, prognostic factors and treatment approaches were retrospectively analyzed.</p><p><strong>Results: </strong>At recurrence, 41 patients underwent surgery, 12 received radiation, 23 received chemotherapy, 12 were under active surveillance, and 6 received best supportive care. In univariate analysis, well-differentiated primary tumors predicted better overall survival (OS) compared to dedifferentiated tumors (p = 0.004). Conversely, shorter recurrence-free survival (RFS) after initial surgery, smaller recurrent tumors at treatment, and high neutrophil-to-lymphocyte ratio (NLR) at recurrence were associated with poorer OS (p = 0.0418, 0.007, and 0.0475, respectively). Treatment decisions were influenced by RFS, time from recurrence to treatment, initial tumor differentiation, recurrence site, and multiplicity. Among those who had surgery for recurrence, 29.2% (12/41) showed a change in tumor differentiation. RFS was a significant predictor of this change (p = 0.026). Additionally, NLR at recurrence and the waiting period from recurrence to treatment were significant prognostic factors in surgically treated patients (p = 0.005 and 0.028, respectively).</p><p><strong>Conclusions: </strong>RFS, timing of treatment, initial tumor differentiation, and recurrence characteristics influence treatment choices at first recurrence. RFS may predict changes in tumor differentiation, while NLR at recurrence and the waiting period from recurrence to treatment are important prognostic indicators in patients undergoing surgery.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1641-1649"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors and the impact of neoadjuvant chemotherapy on the development of metastasis in patients with undifferentiated pleomorphic sarcoma of soft tissue.","authors":"Shinji Miwa, Katsuhiro Hayashi, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Norio Yamamoto, Satoru Demura","doi":"10.1007/s10147-025-02807-0","DOIUrl":"10.1007/s10147-025-02807-0","url":null,"abstract":"<p><strong>Background: </strong>Although undifferentiated pleomorphic sarcoma (UPS), previously termed as malignant fibrous histiocytoma (MFH), is one of the most common soft tissue sarcomas, the number of studies focusing on UPS remains limited. This retrospective study aimed to identify prognostic factors and assess the clinical impact of chemotherapy on the development of metastasis in patients with UPS.</p><p><strong>Methods: </strong>This study included 147 patients with UPS who underwent tumor resection. The associations of various parameters with oncological outcomes were investigated. Furthermore, the efficacy of chemotherapy against the development of metastatic disease has been investigated in patients with localized UPS.</p><p><strong>Results: </strong>5-year disease-specific and local recurrence-free survival rates were 71.7% and 61.6%, respectively. Metastatic disease at diagnosis (hazard ratio [HR], 16.7; P < 0.001) and trunk involvement (HR, 2.6; P = 0.015) were independently associated with disease-specific survival. R1/R2 resection (HR, 2.3; P = 0.008) and metastatic disease at diagnosis (HR, 5.2; P = 0.003) were independently associated with local recurrence-free survival. Among 39 patients who underwent neoadjuvant chemotherapy, 10 (25.6%) showed a good response (tumor necrosis ≥ 90%) to the neoadjuvant chemotherapy, and the responders showed a significantly higher metastasis-free survival rate than non-responders (P = 0.034).</p><p><strong>Conclusions: </strong>This study showed that metastatic disease at diagnosis, trunk involvement, and incomplete resection are risk factors for poor oncological outcomes in patients with UPS, and that effective neoadjuvant chemotherapy decreases metastatic disease. The development of effective anticancer agents and methods for predicting of the chemotherapeutic effects is warranted to improve the clinical outcomes in patients with UPS.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1650-1658"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.","authors":"Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Pegah Jafarinasabian, David Soong, Barbara D'Angelo Månsson, Ami Takahashi, Elena Favaro, Noriko Fukuhara","doi":"10.1007/s10147-025-02788-0","DOIUrl":"10.1007/s10147-025-02788-0","url":null,"abstract":"<p><strong>Background: </strong>Primary results from the EPCORE NHL-3 trial (NCT04542824) showed deep, durable responses in Japanese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with single-agent epcoritamab, a subcutaneous CD3xCD20 bispecific antibody. Here, we report 3-year follow-up of safety and efficacy.</p><p><strong>Methods: </strong>Japanese patients with R/R CD20⁺ DLBCL and  ≥ 2 prior systemic therapies received epcoritamab (0.16/0.8-mg step-up doses, then 48-mg full doses) according to the approved label. The primary endpoint was overall response rate per independent review committee.</p><p><strong>Results: </strong>As of July 12, 2024, 36 patients received epcoritamab (median follow-up, 36.7 months). Overall/complete response rates were 56%/47%. Median duration of response was 15.2 months. Median duration of complete response was not reached; an estimated 53% of complete responders remained in complete response at 3 years. Median progression-free/overall survival (PFS/OS) were 4.1/14.9 months overall; neither was reached among complete responders. Three-year PFS/OS estimates were 25%/39% overall and 53%/71% in complete responders. Among 30 evaluable patients, 17 (57%) became minimal residual disease (MRD) negative, which was associated with longer PFS (cycle 3 day 1 landmark analysis). The most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (83%), injection-site reaction (69%), and neutropenia (39%), consistent with previous reports. No fatal TEAEs occurred.</p><p><strong>Conclusions: </strong>With  > 3 years of follow-up, epcoritamab treatment has consistently shown durable responses and high rates of MRD negativity in Japanese patients with R/R DLBCL. Safety was similar to previous reports. These long-term remissions reaffirm encouraging outcomes with epcoritamab for this challenging-to-treat population.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1631-1640"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of body mass index on D-dimer diagnostic utility for deep vein thrombosis in patients with cancer: a single-center retrospective analysis.","authors":"Yuya Masuda, Tatsuya Konishi, Yoshihiro Yakushijin, Shintaro Yamanaka, Shinji Hasebe, Jun Yamanouchi, Katsuto Takenaka","doi":"10.1007/s10147-025-02787-1","DOIUrl":"10.1007/s10147-025-02787-1","url":null,"abstract":"<p><strong>Background: </strong>Deep vein thrombosis (DVT) is a common complication in cancer patients associated with significant morbidity and mortality. D-dimer is a widely used screening tool for suspected DVT; however, its accuracy may be influenced by body mass index (BMI). We evaluated whether BMI modified the diagnostic utility of D-dimer levels in patients with cancer and DVT.</p><p><strong>Methods: </strong>We retrospectively analyzed 439 patients with newly diagnosed solid cancers suspected of having DVT between January 2013 and December 2020. DVT was confirmed or excluded by using computed tomography or echography. D-dimer was measured, and patients were classified by BMI as low- (< 18.5 kg/m²), normal- (18.5-24.9 kg/m²), or high-BMI (≥ 25.0 kg/m²). D-dimer levels, positive and negative predictive values (PPV and NPV), and overall survival (OS) were compared.</p><p><strong>Results: </strong>Of 439 patients, 175 (39.9%) had DVT. BMI did not differ significantly between the DVT-positive and DVT-negative patients. In the normal and high BMI groups, D-dimer levels were significantly higher in patients with DVT than those without (p < 0.01), whereas patients with a low BMI did not show this difference (p = 0.12). Using a 1 µg/mL cut-off, PPV was 32% in low-, 52% in normal-, and 49% in high-BMI patients; NPV was 83%, 91%, and 97%, respectively. OS did not differ among the BMI groups, and no deaths were directly related to DVT.</p><p><strong>Conclusion: </strong>Diagnostic performance of D-dimer level may diminish in underweight patients with cancer. Clinicians should carefully interpret the D-dimer levels in low-BMI populations and consider additional diagnostic strategies.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1545-1552"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.","authors":"Masaya Takahashi, Hitomi Nakatsukasa, Masahito Shibano, Yusuke Ishigami, Takako Oka, Yoko Tani, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda","doi":"10.1007/s10147-025-02805-2","DOIUrl":"10.1007/s10147-025-02805-2","url":null,"abstract":"<p><strong>Background: </strong>Proton pump inhibitors (PPIs) are well-known inducers of gut dysbiosis because oral bacteria cannot be sterilized owing to their gastric acid-suppressing effect. PPI-induced gut dysbiosis is associated with shorter progression-free survival (PFS) and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Although vonoprazan exhibits more powerful acid suppression than PPIs, its effect on ICI therapy outcomes remains unknown. We evaluated vonoprazan on ICI therapy efficacy in patients with NSCLC.</p><p><strong>Methods: </strong>This retrospective study included patients aged ≥ 18 years with advanced or recurrent NSCLC receiving ICI monotherapy or ICI plus chemotherapy between January 2016 and December 2021 at Osaka Metropolitan University Hospital.</p><p><strong>Results: </strong>Of the 289 patients, 121 received PPIs, 22 received vonoprazan, and 146 did not receive either vonoprazan or PPIs (control group). In multivariate analysis, the PFS in the PPI (hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.21-2.21; p = 0.0014) and vonoprazan groups (HR, 2.49; 95% CI, 1.47-4.23; p < 0.001) were significantly shorter than those in the control group. The OS in the PPI (HR, 1.74; 95% CI, 1.23-2.45; p = 0.0017) and vonoprazan groups (HR, 5.24; 95% CI, 2.88-9.53; p < 0.001) were also significantly shorter than those in the control group.</p><p><strong>Conclusion: </strong>Vonoprazan was associated with worse PFS and OS in patients with NSCLC treated with ICIs than those who did not receive PPIs or vonoprazan. Moreover, vonoprazan may have a more negative impact on ICI therapy efficacy than PPI.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1582-1592"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives.","authors":"Nobuki Imano","doi":"10.1007/s10147-025-02776-4","DOIUrl":"10.1007/s10147-025-02776-4","url":null,"abstract":"<p><p>Oligometastatic disease (OMD) represents an intermediate state between locoregionally advanced and widespread polymetastatic disease, where local therapy may alter disease progression and improve survival. Metastasis-directed therapy (MDT), particularly stereotactic body radiotherapy (SBRT), has been evaluated alongside systemic therapy, yet OMD definitions and criteria for selecting patients who benefit from local therapy remain inconsistent. This review summarizes recent clinical trials on SBRT for OMD across cancer types. The SABR-COMET trial suggested that MDT may improve survival in OMD across various malignancies. In non-small cell lung cancer (NSCLC), phase II and some phase III trials support local therapy's effectiveness, particularly in combination with systemic treatment, though optimal patient selection remains uncertain. In breast cancer, randomized data remain inconclusive, with NRG-BR002 failing to show a survival benefit, highlighting the need for better patient stratification. In prostate cancer, multiple phase II trials suggest that MDT prolongs androgen deprivation therapy (ADT)-free survival, but no phase III trials have confirmed these findings. Emerging data indicate that MDT may also benefit OMD patients with less common primary cancers, including pancreatic and renal cell carcinoma, though further phase III trials are needed. Ongoing research aims to refine patient selection and integrate MDT into clinical practice to optimize outcomes. Standardized OMD definitions, improved biomarkers, and better stratification criteria are crucial to maximizing the benefit of MDT. The results of ongoing phase III trials will be pivotal in determining its role in oligometastatic cancer management.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1505-1521"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of medications on the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic head and neck cancer.","authors":"Kiyoshi Minohara, Takuma Matoba, Michi Sawabe, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Sho Iwaki, Hiroshi Tsuge, Sae Imaizumi, Koji Tsukamoto, Ayano Kondo, Keiichiro Shingaki, Sekai Kikuchi, Tomota Kamida, Funa Arai, Shinichi Iwasaki","doi":"10.1007/s10147-025-02797-z","DOIUrl":"10.1007/s10147-025-02797-z","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) are standard treatments for recurrent or metastatic head and neck cancer (RM-HNC). However, variability in treatment response necessitates the exploration of predictive factors, including gut microbiota, which are influenced by antibiotics, proton pump inhibitors (PPIs), and statins. This retrospective study assessed the effects of these medications on the clinical outcomes of ICI-treated patients with RM-HNC.</p><p><strong>Methods: </strong>This retrospective cohort study included 112 patients with RM-HNC who received nivolumab or pembrolizumab monotherapy between 2017 and 2022 at Nagoya City University Hospital. The effects of medications on overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR) were evaluated using the Kaplan-Meier method and Cox proportional hazards model.</p><p><strong>Results: </strong>Antibiotic administration within 60 days before ICI initiation was significantly associated with worse OS (median OS, 11.9 vs 20.5 months, p = 0.011) and PFS (median PFS, 3.0 vs 5.8 months, p = 0.018). Subgroup analyses indicated that tetracyclines were particularly detrimental. No significant differences in OS or PFS were observed with PPI or statin administration, and no significant associations of ORR or DCR were detected with antibiotic, PPI, or statin administration.</p><p><strong>Conclusion: </strong>Antibiotic administration was associated with worse survival in patients with RM-HNC receiving ICIs. These findings underscore the need for careful consideration of antibiotic administration in patients undergoing ICI therapy and highlight the importance of further research to optimize treatment strategies.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1572-1581"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}